Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

News

Risk Factors
Chinese American Immigrants Face Higher Risk of Cardiovascular Disease Depending on Length of Residence and Location in the U.S. 
09/05/2024
The study observed the heart health of 746 Chinese Americans in both Los Angeles and Chicago over a period of roughly 18 years. Participants who resided in Chicago showed lower mortality levels from heart disease compared to those who lived...
The study observed the heart health of 746 Chinese Americans in both Los Angeles and Chicago over a period of roughly 18 years. Participants who resided in Chicago showed lower mortality levels from heart disease compared to those who lived...
The study observed the heart...
09/05/2024
Cath Lab Digest

Advertisement

Pharmaceutical Therapy
Long-Term Follow-Up Data From Phase 3 Study of Camzyos (mavacamten) Underscores Established Efficacy and Safety Profile in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
09/04/2024
With inclusion in both the ESC and AHA/ACC clinical guidelines as a recommended option for when symptoms persist after first-line therapy, CAMZYOS is a standard of care for symptomatic oHCM.
With inclusion in both the ESC and AHA/ACC clinical guidelines as a recommended option for when symptoms persist after first-line therapy, CAMZYOS is a standard of care for symptomatic oHCM.
With inclusion in both the ESC...
09/04/2024
Cath Lab Digest
Pharmaceutical Therapy
Late-Breaking Kerendia (finerenone) Investigational Data Show Reduction in Cardiovascular Death and Total Heart Failure Events in Adults with Heart Failure With Mildly Reduced or Preserved Ejection Fraction
09/04/2024
Kerendia is the first-and-only non-steroidal mineralocorticoid receptor antagonist (MRA) to meet a primary composite cardiovascular endpoint in a Phase III trial investigating patients with HF and LVEF ≥40%.(1)
Kerendia is the first-and-only non-steroidal mineralocorticoid receptor antagonist (MRA) to meet a primary composite cardiovascular endpoint in a Phase III trial investigating patients with HF and LVEF ≥40%.(1)
Kerendia is the first-and-only...
09/04/2024
Cath Lab Digest
AI
Viz.ai and Cleerly Partner on Heart Disease Evaluation Using Artificial Intelligence
09/04/2024
Cleerly has pioneered the development of several leading FDA-approved softwares that use coronary computed tomography angiography (CCTA) images with advanced AI algorithms to detect ischemia and stenosis, and identify, quantify, and...
Cleerly has pioneered the development of several leading FDA-approved softwares that use coronary computed tomography angiography (CCTA) images with advanced AI algorithms to detect ischemia and stenosis, and identify, quantify, and...
Cleerly has pioneered the...
09/04/2024
Cath Lab Digest

Advertisement

Radiation Protection
AliMed, Inc. Awarded Vizient Contract for Radiation Protection Products
09/04/2024
AliMed's contract covers an extensive range of radiation protection products, featuring off-the-shelf Grab 'n Go™ Aprons with same-day shipping and fully customizable Perfect Fit™ Aprons with tailored sizing and personalization options.
AliMed's contract covers an extensive range of radiation protection products, featuring off-the-shelf Grab 'n Go™ Aprons with same-day shipping and fully customizable Perfect Fit™ Aprons with tailored sizing and personalization options.
AliMed's contract covers an...
09/04/2024
Cath Lab Digest
Imaging
First U.S. Patient Randomized to CT-Guided PCI in P4 Research Trial Accelerating Innovation with Advanced Cardiovascular Imaging
09/03/2024
Minneapolis Heart Institute Foundation® (MHIF) announced the first enrollments in the Precise Procedural and PCI Plan (P4) Research Trial evaluating the potential for advanced cardiovascular imaging to enhance patient care.
Minneapolis Heart Institute Foundation® (MHIF) announced the first enrollments in the Precise Procedural and PCI Plan (P4) Research Trial evaluating the potential for advanced cardiovascular imaging to enhance patient care.
Minneapolis Heart Institute...
09/03/2024
Cath Lab Digest
Bioadaptors
ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action
09/03/2024
The INFINITY-SWEDEHEART Randomized Controlled Trial comparing the novel DynamX® Coronary Bioadaptor System with the contemporary Resolute Onyx™ zotarolimus drug-eluting stent (DES) met its primary endpoint of target lesion failure (TLF)...
The INFINITY-SWEDEHEART Randomized Controlled Trial comparing the novel DynamX® Coronary Bioadaptor System with the contemporary Resolute Onyx™ zotarolimus drug-eluting stent (DES) met its primary endpoint of target lesion failure (TLF)...
The INFINITY-SWEDEHEART...
09/03/2024
Cath Lab Digest

Advertisement

SGLT2 Inhibitors
SGLT2 Inhibitor Empagliflozin Is Shown to Be Safe and Effective for Treating Patients Who Have Suffered a Heart Attack
09/03/2024
EMPACT-MI is the first analysis to determine if it is safe with respect to the kidney to initiate SGLT2 inhibitors in patients during or soon after hospitalization for acute MI. The researchers assessed the therapy’s effects on kidney...
EMPACT-MI is the first analysis to determine if it is safe with respect to the kidney to initiate SGLT2 inhibitors in patients during or soon after hospitalization for acute MI. The researchers assessed the therapy’s effects on kidney...
EMPACT-MI is the first analysis...
09/03/2024
Cath Lab Digest
WOMEN & TAVI
RHEIA Trial: First All-Female TAVI Trial Shows Excellent Outcomes for Women Receiving Edwards Valves
09/03/2024
In the evaluation of composite 1-year endpoints, transcatheter aortic valve implantation (TAVI) was found to be superior to surgical aortic valve replacement (SAVR) with 8.9% of TAVI patients experiencing death, stroke or rehospitalization...
In the evaluation of composite 1-year endpoints, transcatheter aortic valve implantation (TAVI) was found to be superior to surgical aortic valve replacement (SAVR) with 8.9% of TAVI patients experiencing death, stroke or rehospitalization...
In the evaluation of composite...
09/03/2024
Cath Lab Digest
Vertex Pulmonary Embolectomy System (Jupiter Endovascular)
Pulmonary Embolism
Jupiter Endovascular Receives FDA Approval for U.S. Pivotal Study of Vertex Pulmonary Embolectomy System Using Endoportal Control
09/03/2024
Jupiter Endovascular, Inc., developing a new class of endovascular procedures using Endoportal Control™ to bring the precision and control of direct surgical access to catheter-based interventions, announced the U.S. FDA has approved its...
Jupiter Endovascular, Inc., developing a new class of endovascular procedures using Endoportal Control™ to bring the precision and control of direct surgical access to catheter-based interventions, announced the U.S. FDA has approved its...
Jupiter Endovascular, Inc.,...
09/03/2024
Cath Lab Digest

Advertisement

Advertisement

Advertisement

Advertisement

News

Bioadaptors
TCT: DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion Subsets After Six Months
10/29/2024
Data demonstrate significant benefit of the DynamX® Coronary Bioadaptor System compared to a contemporary zotarolimus drug-eluting stent for target lesion failure in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
Data demonstrate significant benefit of the DynamX® Coronary Bioadaptor System compared to a contemporary zotarolimus drug-eluting stent for target lesion failure in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
Data demonstrate significant...
10/29/2024
Cath Lab Digest
Aortic Stenosis
TCT: Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)
10/29/2024
The study analyzed data from over 2 million patients in a real-world database of 29 teaching and non-teaching U.S. health systems.
The study analyzed data from over 2 million patients in a real-world database of 29 teaching and non-teaching U.S. health systems.
The study analyzed data from...
10/29/2024
Cath Lab Digest
Zilver Vena Stent
Zilver Vena Stent Shows High Patency Across All Patient Groups in Three-Year Clinical Study
10/29/2024
Bloomington, Ind. — Cook Medical’s Zilver Vena® Venous Self-Expanding Stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular and Interventional Radiology (JVIR).1 The...
Bloomington, Ind. — Cook Medical’s Zilver Vena® Venous Self-Expanding Stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular and Interventional Radiology (JVIR).1 The...
Bloomington, Ind. — Cook...
10/29/2024
Vascular Disease Management
Coronary Atherectomy
TCT: Treating Severe Calcification With an Atherectomy Device Does Not Improve Cardiac Stenting Outcomes, ECLIPSE Study Finds
10/29/2024
"The use of orbital atherectomy may be reserved for the most extreme cases for which the operator does not believe that balloon angioplasty would be likely to safely cross or pre-dilate the calcified lesion,” said Gregg Stone, MD.
"The use of orbital atherectomy may be reserved for the most extreme cases for which the operator does not believe that balloon angioplasty would be likely to safely cross or pre-dilate the calcified lesion,” said Gregg Stone, MD.
"The use of orbital atherectomy...
10/29/2024
Cath Lab Digest
Large Bore Closure
TCT: Vivasure Announces Positive Results of PATCH IDE Pivotal Study Indicating Safety and Efficacy of PerQseal Large Hole Closure Device
10/29/2024
The Vivasure PerQseal® Closure Device System (PerQSeal) is the first sutureless, fully absorbable synthetic implement for large-bore vessel punctures, and is an alternative to the use of suture- or collagen-based closure devices.
The Vivasure PerQseal® Closure Device System (PerQSeal) is the first sutureless, fully absorbable synthetic implement for large-bore vessel punctures, and is an alternative to the use of suture- or collagen-based closure devices.
The Vivasure PerQseal® Closure...
10/29/2024
Cath Lab Digest
Renal denervation
TCT: SPYRAL HTN-ON MED Study Shows Significant, Consistent, Long-Term Blood Pressure Lowering Effect at Two Years
10/29/2024
"These findings are a key step toward informing the medical community of the long-term effectiveness with radiofrequency renal denervation as a treatment for uncontrolled hypertension," stated Dr. David Kandzari.
"These findings are a key step toward informing the medical community of the long-term effectiveness with radiofrequency renal denervation as a treatment for uncontrolled hypertension," stated Dr. David Kandzari.
"These findings are a key step...
10/29/2024
Cath Lab Digest
EMPOWER CAD Completed Enrollment
Intravascular Lithotripsy
TCT: Shockwave Medical Completes Enrollment in All-Female Coronary IVL Study
10/28/2024
EMPOWER CAD is seeking to confirm the benefits of coronary intravascular lithotripsy (IVL) in female patients with calcified lesions in a post-market, real-world, all-comers population. Primary endpoint results will be presented in 2025, and...
EMPOWER CAD is seeking to confirm the benefits of coronary intravascular lithotripsy (IVL) in female patients with calcified lesions in a post-market, real-world, all-comers population. Primary endpoint results will be presented in 2025, and...
EMPOWER CAD is seeking to...
10/28/2024
Cath Lab Digest
aortic valve stenosis
TCT: Cardiawave Announces Positive Six-Month Data From Valvosoft Pivotal Study
10/28/2024
High-intensity focused ultrasound waves micro-fracture calcification embedded in aortic valve leaflets without damaging tissue. The treatment is designed to be repeatable over time, as needed, to manage disease progression.
High-intensity focused ultrasound waves micro-fracture calcification embedded in aortic valve leaflets without damaging tissue. The treatment is designed to be repeatable over time, as needed, to manage disease progression.
High-intensity focused...
10/28/2024
Cath Lab Digest
Pulmonary Embolism
TCT: RESCUE II Trial Demonstrates the Feasibility of On-The-Table Pharmacomechanical Lysis Without Post-Procedure Infusion in Treating Acute Pulmonary Embolism
10/28/2024
The BASHIR™ Endovascular Catheter was used to deliver 4mg of recombinant tissue plasminogen activator (r-tPA) into each pulmonary artery (PA). The study showed that the independent core laboratory assessed primary endpoint of the right...
The BASHIR™ Endovascular Catheter was used to deliver 4mg of recombinant tissue plasminogen activator (r-tPA) into each pulmonary artery (PA). The study showed that the independent core laboratory assessed primary endpoint of the right...
The BASHIR™ Endovascular...
10/28/2024
Cath Lab Digest
EARLY TAVR
TCT: Groundbreaking Data Demonstrate Superiority of EARLY TAVR in Asymptomatic Severe Aortic Stenosis Patients
10/28/2024
With a median follow up of 3.8 years, the data demonstrated superiority of early TAVR, with 26.8% of the 455 patients in the TAVR arm experiencing death, stroke or unplanned cardiovascular hospitalization compared to 45.3% of the 446 patients...
With a median follow up of 3.8 years, the data demonstrated superiority of early TAVR, with 26.8% of the 455 patients in the TAVR arm experiencing death, stroke or unplanned cardiovascular hospitalization compared to 45.3% of the 446 patients...
With a median follow up of 3.8...
10/28/2024
Cath Lab Digest

Advertisement

Advertisement

Bioadaptors
TCT: DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion Subsets After Six Months
10/29/2024
Data demonstrate significant benefit of the DynamX® Coronary Bioadaptor System compared to a contemporary zotarolimus drug-eluting stent for target lesion failure in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
Data demonstrate significant benefit of the DynamX® Coronary Bioadaptor System compared to a contemporary zotarolimus drug-eluting stent for target lesion failure in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
Data demonstrate significant...
10/29/2024
Cath Lab Digest
Aortic Stenosis
TCT: Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)
10/29/2024
The study analyzed data from over 2 million patients in a real-world database of 29 teaching and non-teaching U.S. health systems.
The study analyzed data from over 2 million patients in a real-world database of 29 teaching and non-teaching U.S. health systems.
The study analyzed data from...
10/29/2024
Cath Lab Digest
Zilver Vena Stent
Zilver Vena Stent Shows High Patency Across All Patient Groups in Three-Year Clinical Study
10/29/2024
Bloomington, Ind. — Cook Medical’s Zilver Vena® Venous Self-Expanding Stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular and Interventional Radiology (JVIR).1 The...
Bloomington, Ind. — Cook Medical’s Zilver Vena® Venous Self-Expanding Stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular and Interventional Radiology (JVIR).1 The...
Bloomington, Ind. — Cook...
10/29/2024
Vascular Disease Management
Coronary Atherectomy
TCT: Treating Severe Calcification With an Atherectomy Device Does Not Improve Cardiac Stenting Outcomes, ECLIPSE Study Finds
10/29/2024
"The use of orbital atherectomy may be reserved for the most extreme cases for which the operator does not believe that balloon angioplasty would be likely to safely cross or pre-dilate the calcified lesion,” said Gregg Stone, MD.
"The use of orbital atherectomy may be reserved for the most extreme cases for which the operator does not believe that balloon angioplasty would be likely to safely cross or pre-dilate the calcified lesion,” said Gregg Stone, MD.
"The use of orbital atherectomy...
10/29/2024
Cath Lab Digest
Large Bore Closure
TCT: Vivasure Announces Positive Results of PATCH IDE Pivotal Study Indicating Safety and Efficacy of PerQseal Large Hole Closure Device
10/29/2024
The Vivasure PerQseal® Closure Device System (PerQSeal) is the first sutureless, fully absorbable synthetic implement for large-bore vessel punctures, and is an alternative to the use of suture- or collagen-based closure devices.
The Vivasure PerQseal® Closure Device System (PerQSeal) is the first sutureless, fully absorbable synthetic implement for large-bore vessel punctures, and is an alternative to the use of suture- or collagen-based closure devices.
The Vivasure PerQseal® Closure...
10/29/2024
Cath Lab Digest
Clinical Images
Coronary Stent and Balloon Entrapment Following Delivery Device Perforation
10/29/2024
The authors present the first reported case of stent and balloon entrapment treated by placing a new stent using the crush technique with intra-coronary optical coherence tomography.
The authors present the first reported case of stent and balloon entrapment treated by placing a new stent using the crush technique with intra-coronary optical coherence tomography.
The authors present the first...
10/29/2024
Journal of Invasive Cardiology
Renal denervation
TCT: SPYRAL HTN-ON MED Study Shows Significant, Consistent, Long-Term Blood Pressure Lowering Effect at Two Years
10/29/2024
"These findings are a key step toward informing the medical community of the long-term effectiveness with radiofrequency renal denervation as a treatment for uncontrolled hypertension," stated Dr. David Kandzari.
"These findings are a key step toward informing the medical community of the long-term effectiveness with radiofrequency renal denervation as a treatment for uncontrolled hypertension," stated Dr. David Kandzari.
"These findings are a key step...
10/29/2024
Cath Lab Digest
EMPOWER CAD Completed Enrollment
Intravascular Lithotripsy
TCT: Shockwave Medical Completes Enrollment in All-Female Coronary IVL Study
10/28/2024
EMPOWER CAD is seeking to confirm the benefits of coronary intravascular lithotripsy (IVL) in female patients with calcified lesions in a post-market, real-world, all-comers population. Primary endpoint results will be presented in 2025, and...
EMPOWER CAD is seeking to confirm the benefits of coronary intravascular lithotripsy (IVL) in female patients with calcified lesions in a post-market, real-world, all-comers population. Primary endpoint results will be presented in 2025, and...
EMPOWER CAD is seeking to...
10/28/2024
Cath Lab Digest
aortic valve stenosis
TCT: Cardiawave Announces Positive Six-Month Data From Valvosoft Pivotal Study
10/28/2024
High-intensity focused ultrasound waves micro-fracture calcification embedded in aortic valve leaflets without damaging tissue. The treatment is designed to be repeatable over time, as needed, to manage disease progression.
High-intensity focused ultrasound waves micro-fracture calcification embedded in aortic valve leaflets without damaging tissue. The treatment is designed to be repeatable over time, as needed, to manage disease progression.
High-intensity focused...
10/28/2024
Cath Lab Digest
Pulmonary Embolism
TCT: RESCUE II Trial Demonstrates the Feasibility of On-The-Table Pharmacomechanical Lysis Without Post-Procedure Infusion in Treating Acute Pulmonary Embolism
10/28/2024
The BASHIR™ Endovascular Catheter was used to deliver 4mg of recombinant tissue plasminogen activator (r-tPA) into each pulmonary artery (PA). The study showed that the independent core laboratory assessed primary endpoint of the right...
The BASHIR™ Endovascular Catheter was used to deliver 4mg of recombinant tissue plasminogen activator (r-tPA) into each pulmonary artery (PA). The study showed that the independent core laboratory assessed primary endpoint of the right...
The BASHIR™ Endovascular...
10/28/2024
Cath Lab Digest

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use